Biognosys announces Nature Communications publication in collaboration with ETH Zurich, Bayer, and BASF
1.9.2020 09:00:00 EEST | Business Wire | Press release
Biognosys is pleased to announce the publication of new research findings in Nature Communications on the utility of its LiP technology and workflow for drug target identification. The publication, entitled “A Machine-Learning-Based Chemoproteomic Approach to Identify Drug Targets and Binding Sites in Complex Proteomes”, is co-authored by collaborators from ETH Zurich, Biognosys, Bayer and BASF.
In this publication, we present a novel chemoproteomic workflow combining LiP and machine learning-based data analysis. This next-generation proteomics approach enables the identification of small molecule drug targets in complex proteomes and the analysis of their binding properties across species and drug target classes.
Oliver Rinner, Chief Executive Officer of Biognosys, comments: “Understanding a compound’s mechanism of action remains a major challenge in drug development. This publication is a testimony to our commitment to support our pharma and biotech partners with unique applications for more efficient drug discovery.”
Lukas Reiter, Chief Technology Officer, states: “Biognosys’ quantitative proteomics technology based on data independent acquisition (DIA) is a perfect fit for the LiP technology. This combined workflow enabled us to develop a target deconvolution approach for human cell lines.”
Prof. Dr. Paola Picotti, Associate Professor in Molecular Systems Biology and head of the Picotti group at ETH Zurich, and Scientific Advisor for Biognosys, says: “With the LiP approach, we can now also identify compound-binding in very complex mammalian cell systems with high confidence. In addition, we get information on binding affinity, which helps us to prioritize targets for follow-up studies.”
Thomas Knobloch, Laboratory Manager at Bayer CropScience, adds: “The LiP technology is a very valuable tool to identify target and off-target of novel compounds whatever the organism and to support the process of target deconvolution in early phase research.”
Earlier this year, Biognosys published research findings demonstrating the utility of LiP-based proteomics for drug discovery at the US Human Proteome (HUPO) Conference and the American Association for Cancer Research (AACR) Annual Meeting.
About Limited Proteolysis (LiP)
The Limited Proteolysis technology coupled to next-generation quantitative mass spectrometry is a novel approach that enables the unbiased and proteome-wide profiling of protein changes resulting from a variety of stimuli such as heat shock, protein-protein interactions, compound binding, and posttranslational modifications.
Invented by the group of Prof. Paola Picotti at ETH Zurich, this patented technology is exclusively licensed to and co-developed by Biognosys to support pharma and biotech partners with contract research services for drug discovery and development. Biognosys already offers a LiP-technology based target deconvolution application and is developing additional, machine-learning-based applications for target validation.
For more information, click here.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science research by developing the most advanced proteomics tools and making them available for pharmaceutical and biotech research and development. The company offers a suite of products and services to decode the proteome and equip researchers from all fields with an in-depth view of protein expression and regulation in cells, tissues, or body fluids. Biognosys’ technology is based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach, for unprecedented quantification of large proteomes in a single experiment. More information at www.biognosys.com
Reference
Piazza I et al. A machine learning-based chemoproteomic approach to identify drug targets and binding sites in complex proteomes. Nature Communications (2020)11:4200.
DOI: 10.1038/s41467-020-18071-x
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005028/en/
Contact information
Media Contact:
Oliver Rinner, PhD
Chief Executive Officer
Phone +41 (0) 44 738 20 40
oliver.rinner@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International’s Moira Gilchrist Positions Human Judgment as a Critical Leadership Advantage Amid Rapid AI Adoption at Wall Street Journal Forum8.5.2026 11:00:00 EEST | Press release
Philip Morris International’s (PMI) (NYSE:PM) Chief Global Communications Officer, Moira Gilchrist, joined global thought leaders at The Wall Street Journal’s Future of Everything conference in New York to examine why human cognition—judgment, context, creativity, and ethical reasoning—is becoming the most valuable asset in an age of artificial intelligence. “The AI boom is putting a premium on distinctly human capabilities,” said Gilchrist, who took part in the session “Cognition: The New Currency – Why Human Judgment Matters More Than Ever.” Speaking to attendees, she emphasized that, “As knowledge is getting democratized, human judgment, intuition, and creativity become the true differentiators that leaders need to nurture across all levels of their organizations.” Philip Morris International is today a different company, built with a singular objective: achieving a smoke-free future. It has evolved its product portfolio, reskilled its workforce, and adopted new ways of working to e
Fortegra Appoints Iwan Röpcke as Chief Executive Officer, Belgium8.5.2026 10:30:00 EEST | Press release
The Fortegra Group, Inc., a global specialty insurer, today announced the appointment of Iwan Röpcke as Chief Executive Officer, Belgium. Mr. Röpcke brings more than 25 years of insurance industry experience to the role, spanning broking, commercial leadership, and executive management across the Benelux and broader European markets. He joins Fortegra from Lloyd’s Insurance Company S.A., where he served as Country Manager for Belgium and the Netherlands, building out the operation from its early stages and overseeing both business strategy and development. Prior to Lloyd's, Mr. Röpcke held senior leadership positions at Willis Towers Watson (via Gras Savoye), where he served as Head of Sales and Head of the Competence Center. His career also includes roles at Inter Partner Assistance (AXA Assistance) as Commercial Director Benelux, Winterthur Europe Assurances, AIG Europe, Aon Belgium, and Marsh. Mr. Röpcke’s industry expertise spans a range of specialty risk areas, with deep relations
KAYTUS Launches All-QLC Flash Storage at AI EXPO 2026 for 10,000-GPU Clusters8.5.2026 10:02:00 EEST | Press release
At AI EXPO KOREA 2026, KAYTUS officially launched its All-QLC Flash Storage Solution, engineered to deliver high performance, massive scalability, and cost efficiency for 10,000-GPU clusters. The solution addresses data-delivery bottlenecks in ultra-large-scale AI training, helping maximize GPU resource utilization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260508313130/en/ Based on the KR2280 and KR1180 server platforms, the solution is deeply integrated with industry-leading AI-native parallel file systems to eliminate data silos inherent in traditional tiered storage. Purpose-built for read-intensive AI workloads, it overcomes the horizontal scaling limitations of massive clusters. Verified test-data shows that, at exabyte-scale deployment, the solution delivers 10 TB/s aggregate bandwidth and 100 million IOPS. In addition, it reduces five-year TCO by 70% compared with traditional TLC-based solutions, accelerating mo
Beneq Appoints Dr. Jason Harrison as Chief Executive Officer8.5.2026 10:00:00 EEST | Press release
Beneq Oy, the home of atomic layer deposition (ALD), today announced the appointment of Dr. Jason Harrison as Chief Executive Officer. Dr. Harrison succeeds Dr. Tommi Vainio and will lead Beneq into its next phase of growth across semiconductor, optical, and emerging technology markets. A Strategic Leadership Transition Beneq enters its next phase of growth from a position of strong commercial momentum. Recent milestones include the qualification of the Beneq Transform® cluster tool for volume production of GaN power and RF filter devices; the introduction of Beneq Transmute™ and Beneq Transform® XP, both engineered for high-volume manufacturing (HVM) of specialty semiconductors; growing adoption of the P-Series for coating critical chamber parts in advanced node devices; and selection of the C2R™ for AR waveguide production in next-generation XR optics. Against this backdrop, the Board of Directors has determined that the time is right to align executive leadership with the company's
World Employment Confederation’s 59th Annual Conference to Address Critical Global Labour Market Concerns8.5.2026 08:12:00 EEST | Press release
Taking place on 12-13 May in Toronto and entitled ‘Grow With Talent’, this year’s World Employment Conference – co-organised with ACSESS – arrives at a time of profound economic uncertainty. This gathering of leaders and experts will help define the path forward for the global labour market and set the stage for discussions at the 114th Session of the International Labour Conference (ILC) in June. Bettina Schaller, President of World Employment Confederation (WEC) says: “The question at the heart of this year’s World Employment Conference is: how will we mobilise the world’s talent to drive growth in an era of disruption?At a time of accelerating AI adoption, rapid demographic change and an uncertain global economic outlook, pressure on labour markets is intensifying. The issue is no longer simply shortages, but how effectively talent is developed, deployed and matched to where it is needed most.” As advocates for the private employment services industry, WEC brings together policymake
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom